Adding the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib to abiraterone acetate plus prednisone delayed disease progression and postponed the onset of symptoms in patients with metastatic ...
The U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) delivered mixed recommendations for ...
An independent advisory committee of the U.S. Food and Drug Administration has recommended the use of AstraZeneca’s (AZN) anti-tumor agent Truqap (capivasertib) as part of a combination regimen for a ...
Nubeqa (darolutamide) received FDA approval for metastatic castration-sensitive prostate cancer, showing significant improvement in radiographic progression-free survival. The ARANOTE trial involved ...
Please provide your email address to receive an email when new articles are posted on . FDA granted approval to darolutamide for metastatic hormone-sensitive prostate cancer. Randomized phase 3 trial ...
Please provide your email address to receive an email when new articles are posted on . Many men with metastatic hormone-sensitive prostate cancer have not received recommended first-line treatment.
Mark Stein, MD, explores managing mHSPC through PSMA PET imaging, tumor burden assessment, and AMPLITUDE trial data while considering clinical context. The widespread adoption of PSMA PET imaging has ...
Oncologic Drugs Advisory Committee (ODAC) has recognized a favorable benefit risk profile for AstraZeneca’s TRUQAP ® (capivasertib) in combination with abiraterone and androgen deprivation therapy ...
US FDA’s ODA committee recommends approval of AstraZeneca’s Truqap for PTEN-deficient metastatic hormone-sensitive prostate cancer: Cambridge, UK Monday, May 4, 2026, 17:00 Hr ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results